183 related articles for article (PubMed ID: 35753044)
1. Contribution of ADAMTS13-independent VWF regulation in sickle cell disease.
Hunt RC; Katneni U; Yalamanoglu A; Indig FE; Ibla JC; Kimchi-Sarfaty C
J Thromb Haemost; 2022 Sep; 20(9):2098-2108. PubMed ID: 35753044
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of von Willebrand factor reactivity in sickle cell disease during vaso-occlusive crisis and steady state.
Sins JWR; Schimmel M; Luken BM; Nur E; Zeerleder SS; van Tuijn CFJ; Brandjes DPM; Kopatz WF; Urbanus RT; Meijers JCM; Biemond BJ; Fijnvandraat K
J Thromb Haemost; 2017 Jul; 15(7):1392-1402. PubMed ID: 28457019
[TBL] [Abstract][Full Text] [Related]
3. ADAMTS13 activity in sickle cell disease.
Schnog JJ; Kremer Hovinga JA; Krieg S; Akin S; Lämmle B; Brandjes DP; Mac Gillavry MR; Muskiet FD; Duits AJ;
Am J Hematol; 2006 Jul; 81(7):492-8. PubMed ID: 16755558
[TBL] [Abstract][Full Text] [Related]
4. Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.
Raife TJ; Cao W; Atkinson BS; Bedell B; Montgomery RR; Lentz SR; Johnson GF; Zheng XL
Blood; 2009 Aug; 114(8):1666-74. PubMed ID: 19541819
[TBL] [Abstract][Full Text] [Related]
5. Haemoglobin blocks von Willebrand factor proteolysis by ADAMTS-13: a mechanism associated with sickle cell disease.
Zhou Z; Han H; Cruz MA; López JA; Dong JF; Guchhait P
Thromb Haemost; 2009 Jun; 101(6):1070-7. PubMed ID: 19492149
[TBL] [Abstract][Full Text] [Related]
6. Degradation of circulating von Willebrand factor and its regulator ADAMTS13 implicates secreted Bacillus anthracis metalloproteases in anthrax consumptive coagulopathy.
Chung MC; Popova TG; Jorgensen SC; Dong L; Chandhoke V; Bailey CL; Popov SG
J Biol Chem; 2008 Apr; 283(15):9531-42. PubMed ID: 18263586
[TBL] [Abstract][Full Text] [Related]
7. Endothelial VWF is critical for the pathogenesis of vaso-occlusive episode in a mouse model of sickle cell disease.
Shi H; Shao B; Gao L; Venkatesan T; McDaniel JM; Zhou M; McGee S; Yu P; Ahamed J; Journeycake J; George JN; Xia L
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2207592119. PubMed ID: 35969769
[TBL] [Abstract][Full Text] [Related]
8. ADAMTS-13-VWF axis in sickle cell disease patients.
Ladeira VS; Barbosa AR; Oliveira MM; Ferreira LGR; de Oliveira Júnior WV; de Oliveira Renó C; Reis EA; Chaves DG; Dusse LMS; Dos Santos HL; de Barros Pinheiro M; Rios DRA
Ann Hematol; 2021 Feb; 100(2):375-382. PubMed ID: 33404693
[TBL] [Abstract][Full Text] [Related]
9. Treatment with recombinant ADAMTS13, alleviates hypoxia/reoxygenation-induced pathologies in a mouse model of human sickle cell disease.
Rossato P; Glantschnig H; Canneva F; Schuster M; Coulibaly S; Schrenk G; Voelkel D; Dockal M; Plaimauer B; Rottensteiner H; Gritsch H; Federti E; Matte A; De Franceschi L; Scheiflinger F; Hoellriegl W
J Thromb Haemost; 2023 Feb; 21(2):269-275. PubMed ID: 36700507
[TBL] [Abstract][Full Text] [Related]
10. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F
Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645
[TBL] [Abstract][Full Text] [Related]
11. VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.
Fogarty H; Ahmad A; Atiq F; Doherty D; Ward S; Karampini E; Rehill A; Leon G; Byrne C; Geoghegan R; Conroy H; Byrne M; Budde U; Schneppenheim S; Sheehan C; Ngwenya N; Baker RI; Preston RJS; Tuohy E; McMahon C; O'Donnell JS
Blood Adv; 2023 Nov; 7(22):6974-6989. PubMed ID: 37773926
[TBL] [Abstract][Full Text] [Related]
12. Zinc and calcium ions cooperatively modulate ADAMTS13 activity.
Anderson PJ; Kokame K; Sadler JE
J Biol Chem; 2006 Jan; 281(2):850-7. PubMed ID: 16286459
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.
Tati R; Kristoffersson AC; Manea Hedström M; Mörgelin M; Wieslander J; van Kooten C; Karpman D
EBioMedicine; 2017 Feb; 16():302-311. PubMed ID: 28139439
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.
Al-Awadhi A; Adekile A; Marouf R
J Thromb Thrombolysis; 2017 Jan; 43(1):117-123. PubMed ID: 27613177
[TBL] [Abstract][Full Text] [Related]
15. The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma.
Chen J; Hobbs WE; Le J; Lenting PJ; de Groot PG; López JA
Blood; 2011 Mar; 117(13):3680-3. PubMed ID: 21300978
[TBL] [Abstract][Full Text] [Related]
16. Relationship of Thrombospondin 1 to von Willebrand Factor and ADAMTS-13 in Sickle Cell Disease Patients of Arab Ethnicity.
Al-Awadhi A; Adekile A; Marouf R
Acta Haematol; 2021; 144(2):182-189. PubMed ID: 32987383
[TBL] [Abstract][Full Text] [Related]
17. Effect of hydroxyurea therapy on intravascular hemolysis and endothelial dysfunction markers in sickle cell anemia patients.
Chenou F; Hounkpe BW; Domingos IF; Tonassé WV; Batista THC; Santana RM; Arcanjo GDS; Alagbe AE; Araújo ADS; Lucena-Araújo AR; Bezerra MAC; Costa FF; Sonati MF; De Paula EV; Dos Santos MNN
Ann Hematol; 2021 Nov; 100(11):2669-2676. PubMed ID: 34453189
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.
Molvarec A; Rigó J; Bõze T; Derzsy Z; Cervenak L; Makó V; Gombos T; Udvardy ML; Hársfalvi J; Prohászka Z
Thromb Haemost; 2009 Feb; 101(2):305-11. PubMed ID: 19190814
[TBL] [Abstract][Full Text] [Related]
19. ADAMTS13 and von Willebrand factor assessment in steady state and acute vaso-occlusive crisis of sickle cell disease.
Demagny J; Driss A; Stepanian A; Anguel N; Affo L; Roux D; Habibi A; Benghezal S; Capdenat S; Coppo P; Driss F; Veyradier A
Res Pract Thromb Haemost; 2021 Jan; 5(1):197-203. PubMed ID: 33537544
[TBL] [Abstract][Full Text] [Related]
20. Truncation of ADAMTS13 by Plasmin Enhances Its Activity in Plasma.
Clark CC; Mebius MM; de Maat S; Tielens AGM; de Groot PG; Urbanus RT; Fijnheer R; Hazenberg BPC; van Hellemond JJ; Maas C
Thromb Haemost; 2018 Mar; 118(3):471-479. PubMed ID: 29534248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
